At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Metformindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
In Brief
A Phase 2 clinical trial evaluating Metformin for Adenocarcinoma of the Endometrium. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this research is to determine the effects of Metformin, a well tolerated drug widely prescribed for treatment of Type 2 Diabetes Mellitus, on endometrium cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Endometrium
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartAug 2013
Primary CompletionAug 2016
Study CompletionJul 2017
TodayJul 2026
First PostedJun 13, 2013
Enrollment StartAug 29, 2013
Primary CompletionAug 10, 2016
Study CompletionJul 10, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.1 years ago
Interventions
Metformindrug